Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
VisMederi srl, Siena, Italy.
Commun Biol. 2022 Sep 2;5(1):903. doi: 10.1038/s42003-022-03849-0.
The SARS-CoV-2 Omicron variant has rapidly replaced the Delta variant of concern. This new variant harbors worrisome mutations on the spike protein, which are able to escape the immunity elicited by vaccination and/or natural infection. To evaluate the impact and susceptibility of different serum samples to the Omicron variant BA.1, samples from COVID-19 patients and vaccinated individuals were tested for their ability to bind and neutralize the original SARS-CoV-2 virus and the Omicron variant BA.1. COVID-19 patients show the most drastic reduction in Omicron-specific antibody response in comparison with the response to the wild-type virus. Antibodies elicited by a triple homologous/heterologous vaccination regimen or following natural SARS-CoV-2 infection combined with a two-dose vaccine course, result in highest neutralization capacity against the Omicron variant BA.1. Overall, these findings confirm that vaccination of COVID-19 survivors and booster dose to vaccinees with mRNA vaccines is the correct strategy to enhance the antibody cross-protection against Omicron variant BA.1.
SARS-CoV-2 的奥密克戎变体迅速取代了令人担忧的德尔塔变体。这种新变体的刺突蛋白上存在令人担忧的突变，能够逃避疫苗接种和/或自然感染引起的免疫。为了评估不同血清样本对奥密克戎变体 BA.1 的影响和易感性，对 COVID-19 患者和接种者的样本进行了测试，以评估它们结合和中和原始 SARS-CoV-2 病毒和奥密克戎变体 BA.1 的能力。与对野生型病毒的反应相比，COVID-19 患者的奥密克戎特异性抗体反应下降幅度最大。由三同源/异源疫苗接种方案或自然 SARS-CoV-2 感染加两剂疫苗接种引起的抗体产生，导致对奥密克戎变体 BA.1 的最高中和能力。总的来说，这些发现证实，对 COVID-19 幸存者进行疫苗接种，并为接种者接种 mRNA 疫苗进行加强剂量，是增强针对奥密克戎变体 BA.1 的抗体交叉保护的正确策略。
